←
AML Hub8,073 posts
AML Hub avatar

AML Hub

@AML_Hub

A global education platform providing clinical updates on acute myeloid leukemia. Intended for HCPs. linktr.ee/AcuteMyeloidLeukem… #leusm

◷ Joined July 2015▧ 5,380 Photos and videos
AML Hub avatar
AML Hub@AML_Hub·Nov 6

⭐ AML Hub spotlight | HOVON 181 AML and cAMeLot-2: Phase III trial designs⭐  The trial designs of two ongoing phase III trials, investigating bleximenib for the treatment of newly diagnosed AML, were shared at #ASH25. Learn more: bit.ly/4iA7dnD #AMLsm #leusm #MedEd

Post attachmentPost attachmentPost attachment
AML Hub avatar
AML Hub@AML_Hub·4h

🎥 The AML Hub was pleased to speak with Emma Searle. We asked, What have we learned from emerging next-generation menin inhibitor data, and how are they evolving? Watch the full video here: bit.ly/4j5PpkS #AMLsm #leusm #MedEd Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.

Post attachment
AML Hub avatar
AML Hub@AML_Hub·8h

We summarize the trial designs of the ongoing phase III HOVON 181 AML and cAMeLot-2 trials investigating bleximenib for the treatment of newly diagnosed AML, in our latest mini module. Explore the full mini module here: bit.ly/4iA7dnD #AMLsm #leusm #MedEd

Post attachment
AML Hub avatar
AML Hub@AML_Hub·Nov 16

🎥 The AML Hub was pleased to speak with Joshua Zeidner. We asked, What progress has been made with first-generation menin inhibitors in AML, and what needs remain? Watch the full video here: bit.ly/4zOzoH1 #AMLsm #leusm #MedEd Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.

Post attachment
AML Hub avatar
AML Hub@AML_Hub·Nov 11

🚨 NEWS 🚨 @BloodCancerUtd launches Dare to Dream REALworld: AML, a patient-centered initiative that will engage current and former pediatric patients with AML and their families to build a dataset of real-world evidence to inform research and future clinical trials. Read more: bit.ly/3VkqKRx #AMLsm #leusm #MedNews #MedEd

Post attachment
AML Hub avatar
AML Hub@AML_Hub·Nov 11

New publication 📝Results from a retrospective study, published in @LeukemiaJnl, show Ven-based therapy significantly improved median OS vs HMA monotherapy in patients with ND AML ineligible for intensive chemotherapy (11.4 vs 8.2 months; HR, 0.66; p < 0.001). Learn more about ND AML: bit.ly/3NSE3Vk #AMLsm #leusm #MedNews #MedEd

Post attachment
AML Hub avatar
AML Hub@AML_Hub·Nov 5

🎥 Eunice Wang discusses potential future applications of menin inhibitors for the treatment of AML, including in sequential treatment approaches and integration into combination regimens. Watch the full video here: bit.ly/3X18qNF #AMLsm #leusm #MedEd Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.

Post attachment
AML Hub avatar
AML Hub@AML_Hub·Nov 4

New publication 📝 Results from an EBMT registry study, published in @BMTjournal, show that ATG demonstrated superior 3-year OS (58.3% vs 50.4%; p = 0.03) vs alemtuzumab when used as GvHD prophylaxis in adults with AML undergoing allo-HSCT from unrelated donors with intermediate-intensity conditioning. Learn more about allo-HSCT in AML: bit.ly/4tj1Wp3 #AMLsm #leusm #MedNews #MedEd

Post attachment
AML Hub avatar
AML Hub@AML_Hub·Nov 2

🎥 The AML Hub was pleased to speak with Eunice Wang. We asked, What does the future hold for next-generation menin inhibition in AML? Watch the full video here: bit.ly/3X18qNF #AMLsm #leusm #MedEd Intended for healthcare professionals. Independently supported by Johnson & Johnson. Funders are allowed no influence.

Post attachment
AML Hub avatar
AML Hub@AML_Hub·Oct 30

New publication 📝 The trial design and rationale for the phase III QuANTUM-Wild trial, evaluating quizartinib + intensive chemotherapy in patients with ND FLT3-ITD-negative AML, were published in Future Oncology. Learn more about FLT3 inhibition in AML: bit.ly/3TWw10D #AMLsm #leusm #MedNews #MedEd

Post attachment
AML Hub avatar
AML Hub@AML_Hub·Oct 30

Where do you see the greatest future value for NGS-based MRD assessment in AML/MDS?